Caris Life Sciences, Irving, Texas, has published new data illustrating that use of the company’s proprietary Adapt biotargeting system can identify differences in protein expression patterns between exosomes from two related prostate cancer cell lines: vertebral cancer of the prostate (VCaP) and lymph node cancer of the prostate (LNCaP).1

David Spetzler, MBA, PhD, Caris Life Sciences.

David Spetzler, MBA, PhD, Caris Life Sciences.

The paper also demonstrates that the Adapt platform allows for the enrichment of polyligands that can distinguish even between different subpopulations of the same disease. The Adapt biotargeting system has the resolution and sensitivity needed to discover differences in protein complexes using exosomes secreted by cancer cells from the same tumor type.

“The results of this research are highly significant, in that they show that the Adapt system can be deployed against multiple cancer types in various biological matrices and offers broad potential applications in biomarker discovery,” says David Spetzler, MBA, PhD, president and chief scientific officer of Caris Life Sciences. “Further, we were able to show that in prostate cancer, Adapt not only discriminated between cancer types but between subtypes of a specific lineage. We anticipate that this could potentially help inform treatment decisions based on the patient’s specific molecular profile in prostate cancer and across a range of tumor types.”

“The differences in the composition of the endosomal sorting complex required ror transport (ESCRT) pathway and associated complexes between exosomes derived from VCaP and LNCaP cells could point to them as novel biomarkers for these different prostate cancers,” says Michael Famulok, PhD, professor of chemical biology at the University of Bonn and coauthor of the study. “We look forward to further investigating this potential and how the Adapt system can be used to gain a greater understanding of the molecular composition of cells across tumor types.”


1. Hornung T, O’Neill HA, Logie SC, et al. Adapt identifies an ESCRT complex composition that discriminates VCaP from LNCaP prostate cancer cell exosomes. Nucleic Acids Res. Epub ahead of print, January 28, 2020; doi: 10.1093/nar/gkaa034.